Method for the disinsertion of vitreous body by an enzyme which disrupts or degrades chondroitin sulfate proteoglycan

• US 5,292,509 A
• Filed: 06/05/1992
• Issued: 03/08/1994
• Est. Priority Date: 04/16/1990
• Status: Expired due to Term

• Current Assignee: Gregory S. Hageman
• Original Assignee: Bethesda Eye Institute
• Inventors: Hageman, Gregory S.
• Primary Examiner(s): Knode, Marian C.
• Application Number:
  US07/894,526
• Time in Patent Office: 641 Days
• Field of Search: 424/94.61, 424/94.62
• US Class Current: 424/94.61
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

A method for selectively and completely disinserting the ocular vitreous body, epiretinal membranes and/or fibrocellular membranes from the neural retina, ciliary epithelium and posterior lens surface of the mammalian eye as an adjunct to vitrectomy comprises administering to the eye an effective amount of a protease-free glycosaminoglycanase enzyme, such as chondroitinase ABC, adapted to disrupt and/or degrade chondroitin sulfate glycosaminoglycan/proteoglycan localized specifically to sites of vitreoretinal adhesion and thereby permit complete disinsertion of the vitreous body and/or epiretinal membranes.

Claims

1. A method for selectively and completely disinserting the ocular vitreous body, epiretinal membranes or fibrocellular membranes from the neural retina, ciliary epithelium and posterior lens surface of the mammalian eye as an adjunct to vitrectomy which comprises administering to said eye an effective amount of an enzyme which disrupts or degrades chondroitin sulfate proteoglycan localized specifically to sites of vitreoretinal adhesion and thereby permit complete disinsertion of said vitreous body and/or epiretinal membranes.

2. A method as set forth in claim 1 wherein said enzyme is a protease-free glycosaminoglycanase.

3. A method as set forth in claim 2 wherein said enzyme is selected from the group consisting of protease-free chondroitinase ABC, chondroitinase AC, chondroitinase B, chondroitin 4-sulfatase, chondroitin 6-sulfatase, hyaluronidase, and β

-glucuronidase.

4. A method as set forth in claim 1 wherein said effective amount is between approximately 1 and 10,000 units of said enzyme.

5. A method as set forth in claim 1 wherein said effective amount is between approximately 50 and 1000 units of said enzyme.

6. A method as set forth in claim 1 wherein said enzyme is administered to said eye by means of intravitreal, subvitreal, sublenticular or posterior chamber administration.

7. A method as set forth in claim 1 wherein said enzyme is administered in the form of a pharmacologically acceptable buffered solution.

8. A method as set forth in claim 7 wherein said solution is buffered with sodium acetate.

9. A method as set forth in claim 3 wherein said enzyme is chondroitinase ABC